Abstract: An optical waveguide, comprising a waveguide substrate (10). A coupling-in area (20) and a coupling-out area (30) are provided on the waveguide substrate (10), the coupling-in area (20) is provided with a coupling-in grating (21), and the coupling-out area (30) comprises a first coupling-out area (31) and a second coupling-out area (32); a first coupling-out grating (41) is provided in the first coupling-out area (31), and a second coupling-out grating (42) is provided in the second coupling-out area (32); the coupling-in grating (21) and the second coupling-out grating (42) are one-dimensional gratings, and the first coupling-out grating (41) is a two-dimensional grating.

Abstract: The present disclosure provides a humanized anti-BASIGIN antibody or antigen binding fragment thereof, which comprises heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 1; optionally further comprise light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 2. The present disclosure also provides a composition comprising the humanized anti-BASIGIN antibody or antigen binding fragment thereof, an isolated nucleic acid sequence encoding the humanized anti-BASIGIN antibody or antigen binding fragment thereof, a vector comprising the nucleic acid, a host cell comprising the vector, and use of the humanized anti-BASIGIN antibody or antigen binding fragment thereof.

Abstract: The present invention provides a clip, including a first clamping portion, a second clamping portion, a connecting portion and a connecting assembly which includes a first connecting part and a second connecting part, where the first connecting part is arranged at a first end of the first clamping portion, and the second connecting part is arranged at a first end of the second clamping portion; and when the first connecting part and the second connecting part are combined, a closed ring structure can be formed by the connecting portion, and a clamping structure can be formed by the first clamping portion and the second clamping portion.

Abstract: The present disclosure provides a system for semantic analysis and automatic solution of a mathematical application problem.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein.

Abstract: Disclosed are a display panel and a preparation method thereof. The display panel includes an array substrate and a plurality of pixel unit groups. Each of the pixel unit groups includes a first pixel unit and a second pixel unit. The first pixel unit includes a first light-emitting unit layer. The second pixel unit includes a second light-emitting unit layer and a third light-emitting unit layer, and the second light-emitting unit layer and the third light-emitting unit layer are sequentially stacked in a direction facing away from the array substrate.

Abstract: The present disclosure provides a humanized anti-BASIGIN antibody or antigen binding fragment thereof, which comprises heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 1; optionally further comprise light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 2. The present disclosure also provides a composition comprising the humanized anti-BASIGIN antibody or antigen binding fragment thereof, an isolated nucleic acid sequence encoding the humanized anti-BASIGIN antibody or antigen binding fragment thereof, a vector comprising the nucleic acid, a host cell comprising the vector, and use of the humanized anti-BASIGIN antibody or antigen binding fragment thereof.

Abstract: The present disclosure discloses a display panel and a display apparatus. The display panel includes a substrate and at least one light-emitting structure disposed on the substrate, the light-emitting structure includes a first light-emitting element and a color conversion light-emitting element, and the first light-emitting element includes a first color light-emitting layer; and the color conversion light-emitting element and the first light-emitting element are disposed on the substrate in a stacking manner in a first direction, the first direction is a direction perpendicular to the substrate, and the color conversion light-emitting element includes a second color light-emitting layer and a third color color conversion layer disposed in the first direction in a stacking manner with the second color light-emitting layer. The present disclosure may improve light-emitting efficiency of a third color in the display panel, and improve brightness and a display effect of the display panel.

Abstract: The present disclosure provides a display panel and a display device. The display panel includes a driving substrate, a pixel unit group, a bottom bonding layer, and at least one interlayer bonding layer. The pixel unit group is disposed on a side of the driving substrate. The pixel unit group includes a plurality of pixel units that are stacked. The pixel unit that is in the pixel unit group and is close to the driving substrate is bonded to the driving substrate through the bottom bonding layer. Adjacent two of the pixel units are bonded to each other through the interlayer bonding layer.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.

Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.

Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.

Abstract: This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.

Abstract: The present invention relates to a ventilating and blanking device for a coal storage Eurosilo. The ventilating and blanking device includes a top blanking pipe, an axial flow fan and a baffle door, the top blanking pipe including a first pipeline and a second pipeline, an air supply pipe is connected to a side wall of the second pipeline, and the baffle door is connected to a driving mechanism; during blanking, the driving mechanism drives the baffle door so as to make the baffle door close the air supply pipe and the axial flow fan is shut off; and during ventilation, the driving mechanism drives the baffle door so as to make the baffle door close the first pipeline, and the axial flow fan is turned on. Compared with the prior art, the present invention has the advantages of ventilation efficiency, good ventilation effect, etc.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: A Micro LED transfer method, a display panel, and a fabrication method of the display panel are provided. The Micro LED transfer method includes: transferring Micro LEDs of at least two colors from growth substrates thereof to a plurality of first temporary substrates, respectively, where a first temporary substrate includes Micro LEDs of the at least two colors; and transferring the Micro LEDs of the at least two colors located on a same first temporary substrate to at least one array substrate. A same array substrate includes Micro LEDs of the at least two colors, and the Micro LEDs of the at least two colors located on the same array substrate are simultaneously transferred. A distance between adjacent Micro LEDs of a same color on the first temporary substrate is smaller than a distance between adjacent Micro LEDs of the same color on the array substrate.

Abstract: Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.